Press releases

Month Year

Email alerts

Mar 24, 2012

Medtronic Resolute® Drug-Eluting Stent Delivers Durable Clinical Outcomes Through Two Years in Major Studies

Recently FDA-Approved, Novel Heart Device Shows Consistently Low Event Rates Across Broad Spectrum of Coronary Artery Disease Patients, Including Those with Diabetes

CHICAGO--(BUSINESS WIRE)--Mar. 24, 2012-- According to new clinical data presented today at ACC.12 –– the 61st Annual Scientific Session & Expo of the American College of Cardiology (ACC)...
Mar 15, 2012

Medtronic Receives Health Canada License for Deep Brain Stimulation Therapy in Refractory Epilepsy Patients

Another Medtronic First in Neuromodulation in Canada

BRAMPTON, Ontario & MINNEAPOLIS--(BUSINESS WIRE)--Mar. 15, 2012-- Medtronic, Inc. (NYSE: MDT) today announced that it has received from Health Canada a license for Medtronic Deep Brain Stimulation...
Mar 14, 2012

Medtronic Announces Public Offering of Senior Notes

MINNEAPOLIS--(BUSINESS WIRE)--Mar. 14, 2012-- Medtronic, Inc. (NYSE:MDT) today announced a registered offering of $675 million of its 3.125% Senior Notes due 2022 and $400 million of its 4.50%...
Mar 7, 2012

Medtronic CFO Gary Ellis to Speak at Barclays Capital Global Healthcare Conference

MINNEAPOLIS--(BUSINESS WIRE)--Mar. 7, 2012-- Medtronic, Inc. (NYSE: MDT), the world’s leading medical technology company, today announced it will participate in the Barclays Capital Global...
Mar 5, 2012

Medtronic Receives CE Mark for Pacemaker Lead That Will Expand Patient Access to MRI Technology

CapSure Sense MRI™ SureScan® Passive Fixation Leads Gives Physicians More MR-Conditional Options

MINNEAPOLIS--(BUSINESS WIRE)--Mar. 5, 2012-- Medtronic, Inc. (NYSE: MDT) today announced the receipt of CE Mark (Conformité Européenne) and launch of the CapSure Sense MRI™ SureScan® pacing...

Show per page

Su	Mo	Tu	We	Th	Fr	Sa

Su	Mo	Tu	We	Th	Fr	Sa